Mercer Global Advisors
GLUE icon

Mercer Global Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Mercer Global Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Sell
10,631
-1,475
-12% -$27.9K ﹤0.01% 2979
2026
Q1 		$199K Buy
12,106
+1,135
+10% +$21.7K ﹤0.01% 2840
2025
Q4 		$172K Buy
+10,971
New +$148K ﹤0.01% 2611

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mercer Global Advisors's GLUE Position: Q2 2026 in Review

Mercer Global Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 12% in Q2 2026, selling an estimated $27.9K and leaving 10,631 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #2979.

Mercer Global Advisors first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Mercer Global Advisors held 10,631 shares of Monte Rosa Therapeutics worth $257K as of Q2 2026.
  • Mercer Global Advisors sold 1,475 Monte Rosa Therapeutics shares in Q2 2026, an estimated $27.9K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2979 holding.
  • Mercer Global Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.